A Cost-Effectiveness Analysis of Newborn Screening for Severe Combined Immunodeficiency in the UK.

ABSTRACT: Severe combined immunodeficiency (SCID) can be detected through newborn bloodspot screening. In the UK, the National Screening Committee (NSC) requires screening programmes to be cost-effective at standard UK thresholds. To assess the cost-effectiveness of SCID screening for the NSC, a decision-tree model with lifetable estimates of outcomes was built. Model structure and parameterisation were informed by systematic review and expert clinical judgment. A public service perspective was used and lifetime costs and quality-adjusted life years (QALYs) were discounted at 3.5%. Probabilistic, one-way sensitivity analyses and an exploratory disbenefit analysis for the identification of non-SCID patients were conducted. Screening for SCID was estimated to result in an incremental cost-effectivenes

SUBMITTER: Bessey A 

PROVIDER: S-EPMC7510246 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature